Clinical trial
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous…
NCT00111553 · Access to Advanced Health Institute (AAHI), Other · Completed
Key facts
| NCT number | NCT00111553 |
|---|---|
| Title | Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis |
| Official title | Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis |
| Lead sponsor | Access to Advanced Health Institute (AAHI), Other |
| Collaborators | Bill and Melinda Gates Foundation |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leishmaniasis, Cutaneous |
| Intervention type | Biological |
| Interventions | Leish-111f + MPL-SE vaccine |
| Enrollment | 45 |
| Start date | Oct 1, 2004 |
| Completion | Aug 1, 2006 |
| First posted | May 24, 2005 |
| Last update posted | Feb 15, 2007 |
| Countries | Brazil |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: